RU2018140131A3 - - Google Patents

Download PDF

Info

Publication number
RU2018140131A3
RU2018140131A3 RU2018140131A RU2018140131A RU2018140131A3 RU 2018140131 A3 RU2018140131 A3 RU 2018140131A3 RU 2018140131 A RU2018140131 A RU 2018140131A RU 2018140131 A RU2018140131 A RU 2018140131A RU 2018140131 A3 RU2018140131 A3 RU 2018140131A3
Authority
RU
Russia
Application number
RU2018140131A
Other languages
Russian (ru)
Other versions
RU2018140131A (ru
RU2745912C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018140131A3 publication Critical patent/RU2018140131A3/ru
Publication of RU2018140131A publication Critical patent/RU2018140131A/ru
Application granted granted Critical
Publication of RU2745912C2 publication Critical patent/RU2745912C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
RU2018140131A 2016-04-19 2017-04-19 Ацетил-лейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции RU2745912C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201606834 2016-04-19
GB1606834.8 2016-04-19
PCT/GB2017/051090 WO2017182802A1 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021107001A Division RU2837641C2 (ru) 2016-04-19 2021-03-17 Ацетиллейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции

Publications (3)

Publication Number Publication Date
RU2018140131A3 true RU2018140131A3 (enExample) 2020-05-14
RU2018140131A RU2018140131A (ru) 2020-05-14
RU2745912C2 RU2745912C2 (ru) 2021-04-02

Family

ID=58633040

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018140131A RU2745912C2 (ru) 2016-04-19 2017-04-19 Ацетил-лейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции

Country Status (27)

Country Link
US (4) US10905670B2 (enExample)
EP (2) EP4501406A3 (enExample)
JP (3) JP7387264B2 (enExample)
KR (4) KR102413754B1 (enExample)
CN (2) CN109069463B (enExample)
AU (2) AU2017252507B2 (enExample)
BR (1) BR112018071547A2 (enExample)
CA (1) CA3021155A1 (enExample)
DK (1) DK3445351T3 (enExample)
ES (1) ES2994242T3 (enExample)
FI (1) FI3445351T3 (enExample)
HR (1) HRP20241552T1 (enExample)
HU (1) HUE069219T2 (enExample)
IL (3) IL310508A (enExample)
LT (1) LT3445351T (enExample)
MD (1) MD3445351T2 (enExample)
MX (2) MX388461B (enExample)
NZ (1) NZ747307A (enExample)
PL (1) PL3445351T3 (enExample)
PT (1) PT3445351T (enExample)
RS (1) RS66142B1 (enExample)
RU (1) RU2745912C2 (enExample)
SG (2) SG11201809031XA (enExample)
SI (1) SI3445351T1 (enExample)
SM (1) SMT202400459T1 (enExample)
WO (1) WO2017182802A1 (enExample)
ZA (1) ZA201806849B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310508A (en) * 2016-04-19 2024-03-01 Intrabio Ltd Acetyl-leucine or its acceptable pharmacy salt for improved mobility and cognitive function
CN109789114A (zh) 2016-08-11 2019-05-21 内在生物技术有限公司 神经退行性疾病的治疗剂
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
US12145899B2 (en) 2018-12-06 2024-11-19 Intrabio Ltd. Deuterated analogs of acetyl-leucine
KR20210135272A (ko) * 2019-03-02 2021-11-12 인트라바이오 리미티드 질환을 치료하기 위한 류신, 아세틸 류신, 및 관련된 유사체
US12171852B1 (en) 2023-07-18 2024-12-24 Sytheon Ltd Composition and methods for regulating melanogenesis
WO2025166100A1 (en) 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
WO2008134844A1 (en) * 2007-05-08 2008-11-13 Multi Formulations Ltd. Branched-chain amino acid composition for improving skeletal muscle protein metabolism
WO2011025518A1 (en) * 2009-08-27 2011-03-03 Albert Einstein College Of Medicine Of Yeshiva University Cognitive function training to improve motor ability
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
IL310508A (en) * 2016-04-19 2024-03-01 Intrabio Ltd Acetyl-leucine or its acceptable pharmacy salt for improved mobility and cognitive function
WO2019079536A1 (en) * 2017-10-18 2019-04-25 Intrabio Ltd THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS

Also Published As

Publication number Publication date
JP2019513814A (ja) 2019-05-30
AU2022256077A1 (en) 2022-11-17
CN109069463A (zh) 2018-12-21
KR102791288B1 (ko) 2025-04-03
KR102632670B1 (ko) 2024-02-01
LT3445351T (lt) 2024-11-25
JP2022024058A (ja) 2022-02-08
MX388461B (es) 2025-03-20
FI3445351T3 (fi) 2024-11-18
ZA201806849B (en) 2019-07-31
HUE069219T2 (hu) 2025-02-28
MD3445351T2 (ro) 2024-12-31
US20250332133A1 (en) 2025-10-30
IL293266A (en) 2022-07-01
RS66142B1 (sr) 2024-12-31
US20230346732A1 (en) 2023-11-02
EP4501406A2 (en) 2025-02-05
KR20220038814A (ko) 2022-03-29
CN109069463B (zh) 2024-07-23
PL3445351T3 (pl) 2025-01-07
IL310508A (en) 2024-03-01
IL293266B2 (en) 2024-07-01
US12329733B2 (en) 2025-06-17
SMT202400459T1 (it) 2025-01-14
DK3445351T3 (da) 2024-11-04
EP3445351A1 (en) 2019-02-27
AU2017252507B2 (en) 2022-07-21
SG11201809031XA (en) 2018-11-29
RU2018140131A (ru) 2020-05-14
IL262379B (en) 2022-07-01
RU2021107001A (ru) 2021-04-12
KR20240018683A (ko) 2024-02-13
KR102413754B1 (ko) 2022-06-27
KR20180134398A (ko) 2018-12-18
CA3021155A1 (en) 2017-10-26
NZ747307A (en) 2025-10-31
US20190083438A1 (en) 2019-03-21
CN118593463A (zh) 2024-09-06
HRP20241552T1 (hr) 2025-01-17
JP2024123087A (ja) 2024-09-10
AU2017252507A1 (en) 2018-11-08
MX2018012739A (es) 2019-06-17
PT3445351T (pt) 2024-11-14
IL262379A (en) 2018-11-29
RU2745912C2 (ru) 2021-04-02
SG10202106190RA (en) 2021-07-29
JP7506046B2 (ja) 2024-06-25
EP3445351B1 (en) 2024-10-16
KR20220093386A (ko) 2022-07-05
US10905670B2 (en) 2021-02-02
JP7387264B2 (ja) 2023-11-28
MX2021014844A (es) 2022-01-18
ES2994242T3 (en) 2025-02-05
EP4501406A3 (en) 2025-03-26
US20210106548A1 (en) 2021-04-15
SI3445351T1 (sl) 2025-04-30
US11998518B2 (en) 2024-06-04
IL293266B1 (en) 2024-03-01
WO2017182802A1 (en) 2017-10-26
BR112018071547A2 (pt) 2019-03-06

Similar Documents

Publication Publication Date Title
CH714036A1 (enExample)
BR122021026889A2 (enExample)
BR112019009201A2 (enExample)
BR112019008128A2 (enExample)
BR112019000781A2 (enExample)
BR112019009262A2 (enExample)
BR112019008107A2 (enExample)
BR202016030146U2 (enExample)
CN303536629S (enExample)
CN303537730S (enExample)
CN303564481S (enExample)
CN303535881S (enExample)
CN303536110S (enExample)
CN303536210S (enExample)
CN303536212S (enExample)
CN303536215S (enExample)
CN303536233S (enExample)
CN303536278S (enExample)
CN303536360S (enExample)
CN303536391S (enExample)
CN303536482S (enExample)
CN303536548S (enExample)
CN303536550S (enExample)
CN303536579S (enExample)
CN303564197S (enExample)